北方药学
北方藥學
북방약학
JOURNAL OF NORTH PHARMACY
2014年
11期
112-113
,共2页
肝癌I号方%经肝动脉化疗栓塞%原发性肝癌%疗效和预后%临床研究
肝癌I號方%經肝動脈化療栓塞%原髮性肝癌%療效和預後%臨床研究
간암I호방%경간동맥화료전새%원발성간암%료효화예후%림상연구
No. 1 Chinese medicine prescription of cancer of the liver%Via hepatic artery embolism%chemotherapy primary liver cancer%the curative effect and prognosis of patients%Clinical research
目的：观察评价肝癌I号方随证加减结合肝动脉化疗栓塞（TACE）治疗对原发性肝癌（PLC）的疗效和患者预后的影响。方法：取2010～2012年收治的PLC患者60例，分为治疗组及对照组。进行TACE治疗后，治疗组用肝癌I号方加减辨证施治，对照组用西医对症治疗。分别于治疗前、治疗后观察T淋巴细胞亚群及NK细胞、瘤体变化、生活质量评分、生存率等指标。结果：治疗组CD3+、CD4+、CD4+/CD8+、NK升高率均明显高于对照组，对照组CD3+、CD4+/CD8+均明显高于治疗组。瘤体大小比较显示治疗组显效率明显高于对照组，但两组总有效率对比无明显差异。治疗组生活质量提高率明显高于对照组；治疗组生活质量下降率明显低于对照组；生活质量稳定者两组之间相比无明显差异。1～5年生存时间治疗组明显高于对照组。结论：服用肝癌I号方结合TACE治疗可明显提升部分PLC患者的免疫功能、延缓瘤体增大、提高生活质量、延长带瘤生存时间，从而改善预后。
目的：觀察評價肝癌I號方隨證加減結閤肝動脈化療栓塞（TACE）治療對原髮性肝癌（PLC）的療效和患者預後的影響。方法：取2010～2012年收治的PLC患者60例，分為治療組及對照組。進行TACE治療後，治療組用肝癌I號方加減辨證施治，對照組用西醫對癥治療。分彆于治療前、治療後觀察T淋巴細胞亞群及NK細胞、瘤體變化、生活質量評分、生存率等指標。結果：治療組CD3+、CD4+、CD4+/CD8+、NK升高率均明顯高于對照組，對照組CD3+、CD4+/CD8+均明顯高于治療組。瘤體大小比較顯示治療組顯效率明顯高于對照組，但兩組總有效率對比無明顯差異。治療組生活質量提高率明顯高于對照組；治療組生活質量下降率明顯低于對照組；生活質量穩定者兩組之間相比無明顯差異。1～5年生存時間治療組明顯高于對照組。結論：服用肝癌I號方結閤TACE治療可明顯提升部分PLC患者的免疫功能、延緩瘤體增大、提高生活質量、延長帶瘤生存時間，從而改善預後。
목적：관찰평개간암I호방수증가감결합간동맥화료전새（TACE）치료대원발성간암（PLC）적료효화환자예후적영향。방법：취2010～2012년수치적PLC환자60례，분위치료조급대조조。진행TACE치료후，치료조용간암I호방가감변증시치，대조조용서의대증치료。분별우치료전、치료후관찰T림파세포아군급NK세포、류체변화、생활질량평분、생존솔등지표。결과：치료조CD3+、CD4+、CD4+/CD8+、NK승고솔균명현고우대조조，대조조CD3+、CD4+/CD8+균명현고우치료조。류체대소비교현시치료조현효솔명현고우대조조，단량조총유효솔대비무명현차이。치료조생활질량제고솔명현고우대조조；치료조생활질량하강솔명현저우대조조；생활질량은정자량조지간상비무명현차이。1～5년생존시간치료조명현고우대조조。결론：복용간암I호방결합TACE치료가명현제승부분PLC환자적면역공능、연완류체증대、제고생활질량、연장대류생존시간，종이개선예후。
Objective:Observe the evaluation of liver cancer in the no. 1 Chinese medicine prescription and subtract combined with hepatic artery embolism chemotherapy (TACE)with conventional therapy for primary liver cancer (PLC)the influence of the curative effect and prognosis of patients.Methods:in 2010~2012 were 60 patients with PLC, divided into the treatment group and control group. After conventional treatment, The treatment group with liver cancer treats no. 1 Chinese medicine prescription and subtract the dialectical, the control group with western medicine symptomatic treatment. And before and after treatment respectively to observe T lymphocyte subsets and NK cells, tumors had changed, the quality of life score, indices such as survival rate.Result:group. Tumors size comparison shows that show the efficiency of treatment group was obviously higher than that of control group, but no difference between the two groups total effective contrast. Life quality improve rate of treatment group was obviously higher than that of control group; The lower quality of life rate of treatment group was obviously lower than the control group; Life quality is stable, no obvious difference compared two groups of the pulp. 1~5 years survival time in treatment group is significantly higher than the control group. Conclusion:Taking no. 1 Chinese medicine prescription of liver cancer combined with conventional treatment can obviously improve immune function in patients with PLC, postpone tumors had increase, improve the quality of life and prolong survival with tumor, so as to improve the prognosis.
